dabigatran has been researched along with Coronary Artery Disease in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 9 (39.13) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatt, DL; Cannon, CP; Hohnloser, SH; Kiss, RG; Kleine, E; Lip, GYH; Navarro Estrada, JL; Nickenig, G; Nordaby, M; Oldgren, J; Ongen, Z; Oude Ophuis, T; Steg, PG; Ten Berg, JM | 1 |
| Arantes, FBB; Baracioli, LM; Barbosa, CJDG; Dalçoquio, TF; Franci, A; Furtado, RHM; Kalil Filho, R; Menezes, FR; Nakashima, CAK; Nicolau, JC; Nomelini, QSS; Ramires, JAF | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Jansky, P; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Seung, KB; Steg, PG; Ten Berg, JM; Zateyshchikov, DA | 1 |
| Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Berry, NC; Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Mauri, L; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Bhatt, DL; Cannon, CP; Gabor Kiss, R; Hohnloser, SH; Leiva, O; Lip, GYH; Miede, C; Navarro Estrada, J; Nickenig, G; Nordaby, M; Oldgren, J; Ongen, Z; Oude Ophuis, T; Steg, PG; Ten Berg, JM; Zeymer, U | 1 |
| Bhatt, DL; Cannon, CP; Costa, F; Hohnloser, SH; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM; Valgimigli, M | 1 |
| Di Fusco, M; Friend, K; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Thomas, L; Yuce, H | 1 |
| Feng, L; Liu, X; Wang, L; Zhou, M | 1 |
| Bhatt, DL; Cannon, CP; Gabriel Steg, P; Halvorsen, S; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Peterson, BE; Ten Berg, JM; Zeymer, U | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Eccleston, DS; Hohnloser, SH; Kim, JM; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Lim, GB | 1 |
| Baser, O; Di Fusco, M; Friend, K; Gupta, K; Hamilton, M; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Steffel, J | 1 |
| Gottsäter, A | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kreuzer, J; Lip, GYH; Mauri, L; Miede, C; Montalescot, G; Nordaby, M; Oldgren, J; Ozkor, M; Steg, PG; Ten Berg, JM; Vardas, P | 1 |
| Doraiswamy, VA; Gesheff, MG; Gurbel, PA; Slepian, MJ; Tantry, US | 1 |
| Shavadia, J; Welsh, RC | 1 |
| Ajjan, RA; Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Franchi, F; Guzman, LA; King, R; Phoenix, F; Rollini, F; Tello-Montoliu, A; Zenni, MM | 1 |
| Andreotti, F; Arnesen, H; Bachmann, F; Baigent, C; Collet, JP; De Caterina, R; Halvorsen, S; Huber, K; Husted, S; Jespersen, J; Kristensen, SD; Lip, GY; Morais, J; Rasmussen, LH; Ricci, F; Sibbing, D; Siegbahn, A; Storey, RF; Ten Berg, J; Verheugt, FW; Wallentin, L; Weitz, JI | 1 |
| Bhatt, DL; Blatchford, J; Brueckmann, M; Cannon, CP; Ellis, SG; Ferreiros Ripoll, E; Gropper, S; Hohnloser, SH; Kimura, T; Kreuzer, J; Lip, GY; Manassie, J; Massaro, JM; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| de Maat, MP; Friedman, J; Jones, RL; Leebeek, FW; Lindeboom, W; Regar, E; Reilly, P; Smits, P; ten Berg, JM; Ulmans, VA; Verheugt, FW; Vranckx, P | 1 |
3 review(s) available for dabigatran and Coronary Artery Disease
| Article | Year |
|---|---|
Antithrombotic therapy: Dual therapy after PCI in AF.
Topics: Antithrombins; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Thromboembolism | 2017 |
Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Warfarin | 2013 |
Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.
Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials as Topic; Coronary Artery Disease; Dabigatran; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
12 trial(s) available for dabigatran and Coronary Artery Disease
| Article | Year |
|---|---|
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2019 |
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2019 |
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Diabetes Mellitus; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2019 |
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Stents; Thromboembolism; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2020 |
Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction | 2021 |
Efficacy and safety of rivaroxaban and ticagrelor in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Rivaroxaban; Ticagrelor; Treatment Outcome | 2021 |
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial.
Topics: Aspirin; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Treatment Outcome; Warfarin | 2021 |
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Elective Surgical Procedures; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Ticagrelor; Warfarin | 2019 |
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Risk Assessment; Stroke; Thromboembolism; Ticagrelor; Warfarin | 2019 |
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 Enzyme System; Dabigatran; Double-Blind Method; Electrodes; Female; Humans; Light; Male; Middle Aged; Nephelometry and Turbidimetry; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Thrombelastography; Thrombosis; Ticlopidine; Vitamin K | 2016 |
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrilla
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Protocols; Coronary Artery Disease; Coronary Thrombosis; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Research Design; Risk Factors; Stents; Stroke; Time Factors; Treatment Outcome; Warfarin | 2016 |
A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients.
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; Blood Coagulation; Coronary Artery Disease; Coronary Thrombosis; Dabigatran; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pyridines; Treatment Outcome | 2013 |
8 other study(ies) available for dabigatran and Coronary Artery Disease
| Article | Year |
|---|---|
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Topics: Aged; Antithrombins; Coronary Artery Disease; Dabigatran; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Platelet Aggregation; Prospective Studies | 2020 |
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Thromboembolism; Ticagrelor; Treatment Outcome; Warfarin | 2020 |
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.
Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Coronary Artery Disease; Dabigatran; Embolism; Female; Health Care Costs; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Peripheral Arterial Disease; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2021 |
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic the
Topics: Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Warfarin | 2021 |
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Myocardial Infarction; Peripheral Arterial Disease; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2018 |
[NOAC in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease].
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Cardiovascular Diseases; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Myocardial Infarction; Myocardial Ischemia; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Sweden; Thiazoles | 2018 |
Acute management of ST-elevation myocardial infarction patients taking dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Artery Disease; Dabigatran; Drug-Eluting Stents; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2013 |